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ABSTRACT
An increased awareness of the impact of group B streptococcus (GBS) infection on neonatal
outcome has prompted several seemingly discordant committee recommendations. Intrapartum
antibiotics are effective in reducing the risk of neonatal morbidity when administered to a colonized
woman who has a clinical condition that places her neonate at high risk for early-onset sepsis.
However, less is known about the efficacy of prophylactic antibiotics in the colonized woman who
does not have obvious risk factors. Some authorities have suggested that providers refrain from
administering intrapartum antibiotics to colonized women who do not have any ofthese risk factors,
primarily due to concerns about potential adverse reactions, selection of resistant pathogens, and
cost-effectiveness. These recommendations may conflict with the desires of an informed woman
who weighs the real, albeit low, risk for serious neonatal disease against the lower perceived risk
of adverse maternal sequelae from allergic reactions to the antimicrobial agents. Selective prophy-
laxis for GBS disease that is limited to the colonized parturient with risk factors has the potential
for creating conflict because maternal beneficence-based obligations of the physician may be at
odds with maternal autonomy-based obligations. We believe that, given all currently available
information, providers have a moral obligation to discuss GBS screening and treatment issues with
patients. The potential for conflict between patient and physician at the time of delivery can be
minimized through the use of preventive ethics, allowing patients to develop advance directives
regarding intrapartum management within the confines of reasonable and cost-effective care. Until
a consensus is reached among experts, the most prudent approach would be to address such issues
proactively and individualize care based upon the overall estimation and anticipation of risk as well
as the patient’s specific desires. (C) 1996 Wiley-Liss, Inc.
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arly-onset neonatal group B streptococcus (GBS)
sepsis, which continues to be a major cause of
neonatal morbidity and mortality, has recently
emerged as a national public-health concern. Several
professional organizations have published specific rec-
ommendations regarding the identification and subse-
quent treatment of GBS genital colonization in expec-
tant women. In 1992, the American Academy of
Pediatrics recommended universal screening of all
pregnant women with rectovaginal cultures at 26-28
weeks gestation and intrapartum chemoprophylaxis
of women with conditions that place their neonates
at "high risk" for early-onset sepsis such as preterm
delivery, prolonged rupture of the membranes, intra-
partum fever, or a previous child afflicted with early-
onset disease. In contrast, the American College of
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Obstetricians and Gynecologists (ACOG) recom-
mended empiric treatment of parturients with risk
factors, even though their colonization status was un-
known. The Centers for Disease Control and Preven-
tion (CDC) recommends that providers adopt a strat-
egy for the prevention of early-onset GBS sepsis and
inform patients regarding the prevention strategy.
One of two strategies is proposed. The first recom-
mends intrapartum antibiotic prophylaxis for women
who deliver prematurely (<37 week gestation) and
offers intrapartum antibiotics to women identified
as carriers through the collection of prenatal screen-
ing cultures at 35-37 weeks gestation, while the sec-
ond strategy proposed is similar to the original ACOG
recommendation cited above. Recently, public senti-
ment has driven several state legislators to propose
legal mandates for universal management guidelines.
Concern about the potential complications and
cost associated with widespread use of intrapartum
antibiotics has been cited as a reason to avoid the
routine use of antimicrobials in women who are
colonized with GBS but who lack identifiable risk
factors. The absence of an endorsement by the
ACOG or the American Academy of Pediatrics for
the use of prophylactic antibiotics in this population
was primarily due to the lack of relevant clinical
information about the potential benefit of such
agents in this population. However, since this group
comprises the majority of colonized women, the
provider must consider the implications of identi-
fying such individuals through routine screening
prior to adopting such a practice. The ACOG has
stated that, if a screening test is performed, a woman
should be informed of the test result and its poten-
tial implications in regard to use of intrapartum
antibiotics for conditions that would place her new-
born at high risk. During such a discussion, many
parturients will intuitively inquire about the poten-
tial risk posed by her colonization status if none of
the aforementioned high-risk conditions are pres-
ent. Although the informed patient may recognize
that her fetus is "low" risk, she is likely to consider
"any" risk unacceptable and unlikely to be dis-
suaded by concerns about "public health" and
"cost-effectiveness." When faced with the potential
for serious harm to their newborns, most women
will choose any reasonable measure to protect their
infants from such harm, even at the risk of incurring
personal risk or discomfort in the process. In the
colonized parturient without risk factors, the pri-
mary issue will center on the potential benefits and
risks of intrapartum prophylactic antibiotics. The
role of maternal participation in the decision to ad-
minister intrapartum prophylaxis was not a focus of
early GBS recommendations.
We will use the framework of ethical principles
applied to perinatal issues, as described by Cher-
venak and McCullough, to explore these issues.
These authors have emphasized the concept of be-
neficience, suggesting that providers use all avail-
able clinical information after carefully analyzing
the individual circumstances and issues facing the
patient and select a management plan expected to
result in the greatest balance of good over harm.
Patient autonomy implies that each individual pa-
tient has unique values, experiences, and beliefs
that enable her to arrive competently at a self-de-
termining decision about her care. In attempting to
determine if providers are justified in withholding
therapy against the patient’s desires, we will exam-
ine closely the potential good and potential harm
associated with the use, or avoidance, ofintrapartum
prophylactic antibiotics in the colonized parturient
without risk factors (Table 1). Finally, we will pro-
pose and describe an antenatal informed consent
process that, hopefully, will enable patients and
providers to develop a management plan that serves
the best interests of all parties and prevents patient-
provider discord.
RISKS ASSOCIATED WITH INTRAPARTUM
CHEMOPROPHYLAXIS
One of the principal concerns about the liberal use
of intrapartum antibiotics is the potential for an
increased incidence of serious perinatal infections
due to resistant organisms such as Escherichia coli.
Investigations in the routine administration of peni-
cillin to newborn infants have failed to conclusively
demonstrate an associated increase in the incidence
of infections caused by penicillin-resistant organ-
isms.5’6 Similarly, studies examining the effects of
intrapartum antibiotic use for prophylaxis of neona-
tal GBS disease have not demonstrated a significant
increase in neonatal infections from nonstreptococ-
cal organisms resistant to penicillin or ampicillin.
6-9
However, investigations examining this issue have
reported results for a relatively small number of
neonates, and large-scale studies of the overall im-
pact of widespread intrapartum antibiotic use on
perinatal infections due to resistant pathogens are
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TABLE I. Summary of potential risks and benefits associated with intrapartum GBS prophylaxis
Risks or benefits Rate Reference
Risk of early-onset GBS disease in neonates born to women with prenatal GBS
colonization and no intrapartum risk factors (in absence of intrapartum
antibiotic prophylaxis)
Risk of early-onset GBS disease in neonates born to women with negative
prenatal GBS cultures and no intrapartum risk factors (in absence of
intrapartum antibiotic prophylaxis)
Risk of early-onset GBS disease in neonates born to women with prenatal GBS
colonization and one or more intrapartum risk factors (in absence of
intrapartum antibiotic prophylaxis)
Efficacy of intrapartum antimicrobial prophylaxis against early-onset GBS
disease
Reduction in total GBS-related health-care costs with one of the currently
recommended prevention strategies
Risk of allergic reactions to penicillin
Risk of anaphylaxis to penicillin
Risk of fatality from anaphylactic shock among patients treated with penicillin
(note: one-third of fatalities in persons who had previously reacted to
penicillin)
Risk of increased antimicrobial resistance among bacteria causing perinatal
infections following intrapartum antimicrobials
in 200 (5. I/I,000) 18
in 3,200 (0.3/I,000) 18




0.015-0.004% (4-15/I 00,00) 13
0.0015-0.002% (I-2/100,000) 13
Not known; theoretic concern
currently not available. While widespread intrapar-
turn antibiotics remain a legitimate theoretical con-
cern, there is no current evidence that the liberal
use of limited-spectrum penicillins in the peripar-
tum period has adversely effected the spectrum of
these agents or promoted the emergence ofresistant
organisms over the past several decades.1
The use of intrapartum antimicrobial agents may
have a direct impact upon neonatal management,
as some pediatricians may elect to begin empiric
antimicrobial therapy or pursue additional labora-
tory evaluation of an asymptomatic neonate solely
because of intrapartum antibiotic exposure.
1 The
guidelines of the American Academy of Pediatrics
provide several recommendations for the manage-
ment of asymptomatic newborns who have been
exposed to intrapartum antibiotics. However, these
recommendations, which are not based upon pub-
lished trials, may not be acceptable to some pediatri-
cians. Extensive neonatal laboratory evaluations or
routine antimicrobial therapy for all infants exposed
to intrapartum antibiotics would undoubtedly pro-
long hospitalization, having a negative impact on
cost-effectiveness and the potential for good over
harm. Therefore, the management practices of the
individual neonatal providers need to be considered
carefully prior to the administration of intrapartum
antibiotics to colonized women without risk factors.
Some authors have estimated that a significant
number of major adverse reactions, principally fatal
analphylaxis, would occur annually if universal anti-
biotic prophylaxis were utilized for all GBS carri-
ers.2 The estimated risk of fatal anaphylaxis from
penicillin-type agents is approximately 1:100,000;
however, this estimate may not be directly applica-
ble to a relatively young and healthy population of
parturients who would be receiving these agents in
an inpatient setting.
3 Nevertheless, there have
been anecdotal reports of adverse reactions to anti-
microbial agents prescribed for GBS prophylaxis
that have resulted in serious morbidity. 14’15
RISKS ASSOCIATED WITH AVOIDANCE OF
INTRAPARTUM CHEMOPROPHYLAXIS
The incidence of early-onset GBS sepsis in a neo-
nate delivered to a colonized parturient without
established risk factors is approximately 0.5%, and
the mortality rate in the infected infant is about
2-3%. 7’12’16 In a recent population-based, case-con-
trol study of infants with early-onset GBS sepsis,
Schuchat et al. 17 found that 77% of the cases were
in term neonates, with approximately 25% of the
bacteremic neonates having no established risk fac-
tors. In a large multicenter study of neonatal sepsis,
Weisman et al. a6 similarly found a substantial per-
centage of cases of early-onset GBS sepsis in term
neonates without risk factors and determined that
such an infection increased the neonatal mortality
rate 40-fold relative to term neonates without sep-
sis. However, while the majority of infections occur
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in term neonates, the overall attack rate in term
infants without risk factors is relatively low com-
pared with preterm neonates or term infants deliv-
ered towomen with risk factors. With this low attack
rate, the efficacy of intrapartum antibiotics in inter-
rupting vertical transmission to these neonates re-
mains unclear because appropriate randomized clin-
ical trials with sufficient power to detect a benefit
have not been done. Despite the lack of objective
evidence, several investigators have suggested that
the efficacy of such therapy is equivalent to, or
superior to, treatment of the neonates with risk
factors7,8’18 and have proposed that such therapy be
offered to all colonized parturients. 7’8
BENEFITS OF WITHHOLDING
INTRAPARTUM CHEMOPROPHYLAXIS
The avoidance of intrapartum antibiotic therapy
probably increases the likelihood that neonates de-
livered to colonized, "low-risk" parturients will
have routine neonatal courses free of the encum-
brance of laboratory evaluations and antibiotic ther-
apy which might occur if their mother received
intrapartum antibiotics.8’11’14 The weight of this fac-
tor may vary considerably among institutions and
neonatal providers dependent upon local manage-
ment practices. Additionally, the avoidance of intra-
partum antibiotics will reduce the possibility of ad-
verse maternal reactions to medications and lower
overall maternal hospital costs. However, 2 recent
decision analyses have suggested that the treatment
of all colonized parturients is still a cost-effective
approach when the net costs ofmaternal and neona-
tal care of such a preventive strategy are applied to
a large population. 12’9
BENEFITS OF ADMINISTERING
INTRAPARTUM CHEMOPROPHYLAXIS
Current evidence supports the concept that the risk
of acquiring neonatal and maternal infection from
GBS is a continuum related to multiple factors,
rather than an absolute categorical designation. Ad-
ditionally, there is no biologic reason to expect that
antibiotics are less efficacious in colonized women
without risk factors than in women with prolonged
rupture of the membranes, amnionitis, or preterm
delivery, the bacterial inoculum present in the up-
per genital tract is likely to be substantially less in
women without risk factors compared with those
with amnionitis or prolonged rupture of the mem-
branes. Therefore, the potential for successful pro-
phylaxis may be greater in the former group. A
recent meta-analysis concluded that there was a 30-
fold reduction in the incidence of early-onset GBS
neonatal infection associated with intrapartum anti-
biotic prophylaxis and that this risk reduction did
not differ between subgroups of women with or
without risk factors,z In contrast, a different group
of investigators, using more stringent guidelines for
critically reviewing published randomized, con-
trolled trials, concluded that there is a lack of con-
clusive evidence that intrapartum chemoprophy-
laxis reduces perinatal GBS infections in any
population. Therefore, although the majority of
studies suggest that the administration of intrapar-
turn antibiotics reduces vertical transmission of
GBS, the magnitude of the overall benefit for spe-
cific populations of parturients has not been
defined.
If prophylaxis is routinely delayed until estab-
lished risk factors are present, patients with pro-
tracted labor may develop intraamniotic infection,
thus placing themselves and their infants at greater
risk of morbidity. Yancey et al. zl recently showed
that lower-genital-tract GBS colonization was an
independent risk factor for the development of
chorioamnionitis. In turn, symptomatic intraamnio-
tic infection subsequently increased the likelihood
that the neonate would become infected in spite
of intrapartum antimicrobial therapy. Moreover,
Ascher et al.zz recently reported a series of 96 neo-
nates with GBS sepsis. Eighteen of the mothers
had received intrapartum chemoprophylaxis and 16
of their neonates had early-onset disease, while the
remaining 2 had late-onset infections. Of the 16
bacteremic neonates with early-onset disease after
intrapartum antibiotic exposure, 13 were delivered
to women who had been treated for chorioamnio-
nitis. Both of these studies indicate that delaying
antimicrobial therapy until the mother has a clini-
cally apparent intraamniotic infection may reduce
the effectiveness of therapy. Accordingly, one can
postulate that antibiotic therapy early in the intra-
partum period may reduce the incidence of as-
cending infection in colonized parturients, with a
subsequent decrease in the incidence of early-onset
neonatal sepsis and maternal chorioamnionitis;
however, this premise remains unproven.
An additional benefit, which may be difficult to
quantitate, is the avoidance of added apprehension
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for the parturient who will likely be aware of her
colonization status and its potential implications.
Our anecdotal experience suggests that this is a
very real concern for parturients. While the overall
benefit of intrapartum chemoprophylaxis remains
debatable in a population ofcolonized women with-
out risk factors, the majority of such women receiv-
ing prophylaxis find solace in the concept that they
are pursuing an aggressive, rational means of pre-
venting neonatal morbidity.
Finally, the liberal use of intrapartum antibiotics
is likely to ease providers’ concerns about potential
legal recourse in the event of serious neonatal mor-
bidity or mortality related to early-onset sepsis.
While this factor should not be used as justification
for the routine use of intrapartum antibiotics, recent
attention directed at perinatal GBS infections by
the legal community has undoubtedly had an im-
pact on the prescribing practices of some providers.
DISCUSSION
For this article, we chose not to examine the issue
of whether a practitioner should obtain antenatal
GBS screening cultures. Rather, we have focused
on the potential for patient-provider conflict if a
screening test is obtained and the colonized parturi-
ent does not have a clinical condition that would
warrant classification as high-risk and prompt pro-
phylactic antimicrobial therapy. In most obstetric
populations, only 15-25% of the colonized women
will have risk factors that would warrant intrapartum
therapy under most currently published committee
recommendations. Consequently, most colonized
parturients, who will not develop intrapartum risk
factors, are at risk for conflict with their providers
unless there is a clear agreement about the specific
intrapartum management plan. Controversy about
the efficacy of prophylaxis, variations in patient de-
mographics, and individual management practices
currently preclude the development and applica-
tion of a single management algorithm for the colo-
nized parturient without risk factors. Clinically ap-
plied preventive ethics can provide a useful
framework for meaningful discussions between pa-
tient and provider which should result in an under-
standing between both parties of the patient’s pref-
erences and the clinician’s judgment in regard to
intrapartum antimicrobial prophylaxis.
Physicians may elect to forego prophylactic ther-
apy for low-risk women, motivated by beneficence-
based issues related to the potential for adverse
sequelae in their specific patients as well as the
collective good of the population at large (reducing
the potential for the emergence of resistant mi-
crobes and containing health-care costs). Viewed
from a pure public-health perspective, withholding
intrapartum therapy from "low-risk" women may
seem appropriate. However, such a beneficence-
based decision must be substantiated sufficiently
by current clinical information to warrant overriding
the patient’s autonomy-based decision to receive
intrapartum chemoprophylaxis. Conversely, provid-
ers should not intrusively assume that all colonized
parturients without risk factors will desire intrapar-
tum prophylaxis, as some women will likely view
the potential for adverse maternal reactions or al-
tered neonatal management as sufficient basis for
declining therapy.
We do not feel that health-care cost containment
should be used as a rationale for avoiding screening
cultures or the subsequent withholding of antibiot-
ics from colonized parturients. Investigations em-
ploying decision-analysis techniques have shown
that prenatal screening and intrapartum prophylaxis
of all colonized women is cost-effective when total
health-care costs are considered, lz’19 The empiric
intrapartum prophylaxis of unscreened parturients
who are preterm or have prolonged rupture of the
membranes, as suggested by the ACOG, has simi-
larly been shown to be cost-effective by these inves-
tigations. Therefore, we suggest that GBS preven-
tion be considered an integral and necessary part
of prenatal care based upon the current evidence
that such prevention is medically, morally, and fis-
cally justified.
A proposal for the application of preventive eth-
ics has been previously applied to the issue of rou-
tine ultrasound in pregnancy with the systematic
application of the informed consent process sug-
gested as the primary means of resolution,z3 The
suggestion that such an approach be adapted in
the management of GBS colonization may seem
intuitive to some; however, based upon recent prac-
tice surveys, substantial variation in management
for parturients and neonates with respect to GBS
screening and treatment is apparent, za’z5 Current
management practices range from the rigid adher-
ence to published guidelines, i.e., withholding in-
trapartum antimicrobial agents to colonized parturi-
ents without risk factors, to the paternalistic
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administration of intrapartum antibiotics to all colo-
nized women without the allowance for maternal
input in the decision to treat. This variation is likely
due to several factors, some of which have global
application such as the lack of consensus among
experts regarding the ideal management approach
and others which are locally important such as popu-
lation demographics or neonatal management prac-
tices. Additionally, there are ever-looming concerns
about the potential legal repercussions of either
failing to provide intrapartum prophylaxis to all col-
onized women, particularly in light of the widely
held premise that the majority of early-onset GBS
infections are preventable, or a serious adverse reac-
tion following the administration of antibiotics to a
colonized woman without risk factors.
Each patient must be well informed in order to
make an appropriate and reasonable decision re-
garding her care; thus, an ongoing dialogue between
provider and patient is the best approach to pre-
venting conflict. The informed-consent process is
a critical step in the course of empowering patients
to make autonomous decisions. This process re-
quires an unbiased presentation of factual informa-
tion relevant to the circumstances and issues in a
manner which optimizes the patient’s understand-
ing of the crucial points, followed by a proposal or
recommendation by the provider of a management
plan judged to provide the greatest potential good
over harm and, finally, the subsequent acceptance
or refusal ofthe plan by the patient. A formal, candid
discussion and informed consent proceeding have
the potential benefit of fostering patient-provider
rapport by actively demonstrating respect for pa-
tient autonomy. A crucial step in the informed-
consent process is to verify that the patient has a
reasonable understanding of the relevant issues and
an appropriate amount of time to arrive at an appro-
priate decision. Accordingly, the appropriate time
for such a discussion is in the antenatal period,
well before the anticipated onset of labor. Most
importantly, addressing such issues antenatally will
help avoid acute intrapartum conflicts between pa-
tient and provider. Additionally, the well-informed
patient may be a safeguard against failure of a treat-
ment protocol since she may serve as a valuable
resource for prenatal culture results and previously
discussed management plans in the event that pre-
natal records or data are unavailable at the time
of admission.
We are not suggesting that providers acquiesce
to unreasonable or unfounded consumer pressure.
Rather, we suggest that, in the face of a paucity of
decisive clinical data, clinicians should support and
respect the parturient’s ability to direct her treat-
ment within acceptable clinical bounds. Importan-
tly, beneficence-based concerns cannot be com-
pletely abandoned in favor of autonomy-based
obligations, and patient care must remain within
the confines of reasonable and cost-effective man-
agement. In the event that the provider disagrees
with this course of action, he or she is certainly free
to recommend and document a dissenting opinion.
However, the failure to disclose all reasonable thera-
peutic alternatives impairs the women’s ability to
arrive at an autonomous decision suited to her own
beliefs and perceptions. Therefore, the manage-
ment issues surrounding GBS colonization cannot
be ignored or trivialized. We suggest that providers
take a proactive approach to this issue in caring
for their patients, rather than passively waiting for
patients to broach the subject. Additionally, we
believe that women should be empowered with
the necessary knowledge and opportunity to choose
a reasonable management plan. Only through
thoughtful and accurate discussions related to the
issues surrounding GBS colonization can women
and their physicians avoid unsettling conflict.
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